237 related articles for article (PubMed ID: 20350588)
1. Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation.
Hackler EA; Byun NE; Jones CK; Williams JM; Baheza R; Sengupta S; Grier MD; Avison M; Conn PJ; Gore JC
Neuroscience; 2010 Jun; 168(1):209-18. PubMed ID: 20350588
[TBL] [Abstract][Full Text] [Related]
2. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice.
Galici R; Jones CK; Hemstapat K; Nong Y; Echemendia NG; Williams LC; de Paulis T; Conn PJ
J Pharmacol Exp Ther; 2006 Jul; 318(1):173-85. PubMed ID: 16608916
[TBL] [Abstract][Full Text] [Related]
3. The mGluR2 positive allosteric modulator BINA decreases cocaine self-administration and cue-induced cocaine-seeking and counteracts cocaine-induced enhancement of brain reward function in rats.
Jin X; Semenova S; Yang L; Ardecky R; Sheffler DJ; Dahl R; Conn PJ; Cosford ND; Markou A
Neuropsychopharmacology; 2010 Sep; 35(10):2021-36. PubMed ID: 20555310
[TBL] [Abstract][Full Text] [Related]
4. A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis.
Benneyworth MA; Xiang Z; Smith RL; Garcia EE; Conn PJ; Sanders-Bush E
Mol Pharmacol; 2007 Aug; 72(2):477-84. PubMed ID: 17526600
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine.
Gozzi A; Large CH; Schwarz A; Bertani S; Crestan V; Bifone A
Neuropsychopharmacology; 2008 Jun; 33(7):1690-703. PubMed ID: 17805312
[TBL] [Abstract][Full Text] [Related]
6. Effects of group II metabotropic glutamate receptor modulation on ethanol- and sucrose-seeking and consumption in the rat.
Windisch KA; Czachowski CL
Alcohol; 2018 Feb; 66():77-85. PubMed ID: 29220747
[TBL] [Abstract][Full Text] [Related]
7. The mGlu₅ positive allosteric modulator LSN2463359 differentially modulates motor, instrumental and cognitive effects of NMDA receptor antagonists in the rat.
Gastambide F; Gilmour G; Robbins TW; Tricklebank MD
Neuropharmacology; 2013 Jan; 64():240-7. PubMed ID: 22884612
[TBL] [Abstract][Full Text] [Related]
8. Effects of N-acetylaspartylglutamate (NAAG) peptidase inhibition on release of glutamate and dopamine in prefrontal cortex and nucleus accumbens in phencyclidine model of schizophrenia.
Zuo D; Bzdega T; Olszewski RT; Moffett JR; Neale JH
J Biol Chem; 2012 Jun; 287(26):21773-82. PubMed ID: 22570482
[TBL] [Abstract][Full Text] [Related]
9. Role of the simultaneous enhancement of NMDA and dopamine D1 receptor-mediated neurotransmission in the effects of clozapine on phencyclidine-induced acute increases in glutamate levels in the rat medial prefrontal cortex.
Abekawa T; Ito K; Koyama T
Naunyn Schmiedebergs Arch Pharmacol; 2006 Dec; 374(3):177-93. PubMed ID: 17103144
[TBL] [Abstract][Full Text] [Related]
10. Effects of single and repeated phencyclidine administration on the expression of metabotropic glutamate receptor subtype mRNAs in rat brain.
Abe S; Suzuki T; Ito T; Yamaguchi M; Baba A; Hori T; Kurita H; Shiraishi H; Okado N
Neuropsychopharmacology; 2001 Aug; 25(2):173-84. PubMed ID: 11425501
[TBL] [Abstract][Full Text] [Related]
11. mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia.
Engel M; Snikeris P; Matosin N; Newell KA; Huang XF; Frank E
Psychopharmacology (Berl); 2016 Apr; 233(8):1349-59. PubMed ID: 26861891
[TBL] [Abstract][Full Text] [Related]
12. Different effects of a single and repeated administration of clozapine on phencyclidine-induced hyperlocomotion and glutamate releases in the rat medial prefrontal cortex at short- and long-term withdrawal from this antipsychotic.
Abekawa T; Ito K; Koyama T
Naunyn Schmiedebergs Arch Pharmacol; 2007 Jun; 375(4):261-71. PubMed ID: 17458542
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide].
Satow A; Maehara S; Ise S; Hikichi H; Fukushima M; Suzuki G; Kimura T; Tanak T; Ito S; Kawamoto H; Ohta H
J Pharmacol Exp Ther; 2008 Aug; 326(2):577-86. PubMed ID: 18487514
[TBL] [Abstract][Full Text] [Related]
14. The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity.
Henry SA; Lehmann-Masten V; Gasparini F; Geyer MA; Markou A
Neuropharmacology; 2002 Dec; 43(8):1199-209. PubMed ID: 12527469
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists.
Nakazato A; Kumagai T; Sakagami K; Yoshikawa R; Suzuki Y; Chaki S; Ito H; Taguchi T; Nakanishi S; Okuyama S
J Med Chem; 2000 Dec; 43(25):4893-909. PubMed ID: 11123999
[TBL] [Abstract][Full Text] [Related]
16. Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition.
Schlumberger C; Schäfer D; Barberi C; Morè L; Nagel J; Pietraszek M; Schmidt WJ; Danysz W
Behav Pharmacol; 2009 Feb; 20(1):56-66. PubMed ID: 19179851
[TBL] [Abstract][Full Text] [Related]
17. The group II metabotropic glutamate receptor agonist (-)-2-oxa-4-aminobicyclo[3.1.0.]hexane-4,6-dicarboxylate (LY379268) and clozapine reverse phencyclidine-induced behaviors in monoamine-depleted rats.
Swanson CJ; Schoepp DD
J Pharmacol Exp Ther; 2002 Dec; 303(3):919-27. PubMed ID: 12438510
[TBL] [Abstract][Full Text] [Related]
18. NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR.
Olszewski RT; Bukhari N; Zhou J; Kozikowski AP; Wroblewski JT; Shamimi-Noori S; Wroblewska B; Bzdega T; Vicini S; Barton FB; Neale JH
J Neurochem; 2004 May; 89(4):876-85. PubMed ID: 15140187
[TBL] [Abstract][Full Text] [Related]
19. The glycine/NMDA receptor antagonist, R-(+)-HA-966, blocks activation of the mesolimbic dopaminergic system induced by phencyclidine and dizocilpine (MK-801) in rodents.
Bristow LJ; Hutson PH; Thorn L; Tricklebank MD
Br J Pharmacol; 1993 Apr; 108(4):1156-63. PubMed ID: 8485625
[TBL] [Abstract][Full Text] [Related]
20. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity.
Galici R; Echemendia NG; Rodriguez AL; Conn PJ
J Pharmacol Exp Ther; 2005 Dec; 315(3):1181-7. PubMed ID: 16123306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
